Samuel C. Blackman - Dec 1, 2021 Form 4 Insider Report for Day One Biopharmaceuticals, Inc. (DAWN)

Signature
/s/ Charles N. York II, as Attorney-in-Fact
Stock symbol
DAWN
Transactions as of
Dec 1, 2021
Transactions value $
-$172,242
Form type
4
Date filed
12/3/2021, 06:19 PM
Previous filing
May 26, 2021
Next filing
Jan 5, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DAWN Common Stock Gift $0 -1M -41.9% $0.00 1.39M Oct 22, 2021 Direct F1
transaction DAWN Common Stock Gift $0 +1M $0.00 1M Oct 22, 2021 By the 2021 Blackman Family LLC F1
transaction DAWN Common Stock Sale -$84.6K -5.09K -0.37% $16.62 1.38M Dec 1, 2021 Direct F2, F3
transaction DAWN Common Stock Sale -$80.2K -4.5K -0.33% $17.81 1.38M Dec 1, 2021 Direct F2, F4
transaction DAWN Common Stock Sale -$7.46K -409 -0.03% $18.24 1.38M Dec 1, 2021 Direct F2, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On October 22, 2021, the Reporting Person contributed 1,000,000 shares of the Issuer's Common Stock to the 2021 Blackman Family LLC (the "Trust"), of which the Reporting Person is the sole manager, and has shared voting and dispositive power with his wife as members. The Reporting Person continues to report beneficial ownership of all of the Issuer's Common Stock held by the Trust but disclaims beneficial ownership except to the extent of his and his wife's pecuniary interest therein.
F2 The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.
F3 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.19 to $17.15 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.20 to $18.18 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.22 to $18.29 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.